同位素稀释-超高效液相色谱-串联质谱技术分析人血浆中利奈唑胺的浓度

目的:建立超高效液相色谱-串联质谱法和同位素稀释内标法分析人血浆中利奈唑胺浓度的方法.方法:血浆样本经乙腈稀释沉淀蛋白进行前处理,以同位素利奈唑胺-d3为内标,采用Acquity UPLC(c)BEH-C18色谱柱(2.1 mm×50mm,1.7 μm)分离,流动相包括水(含0.1%甲酸,V/V)和乙腈(含0.1%甲酸,V/V),梯度洗脱,流速为0.3 ml/min.正离子检测模式下,采用多离子反应监测模式进行分析.结果:利奈唑胺浓度在0.078~10.000 μg/ml范围内线性关系良好,定量限为0.078 μg/ml;日内、日间RSD均<6%;提取回收率〉90%.结论:本方法操作简便、快速...

Full description

Saved in:
Bibliographic Details
Published in中国医院用药评价与分析 Vol. 17; no. 5; pp. 581 - 583
Main Author 王晓雪 车仙花 崔刚 张相林
Format Journal Article
LanguageChinese
Published 卫生部中日友好医院药学部,北京,100029%延边大学附属医院药学部,吉林 延吉,133000 2017
Subjects
Online AccessGet full text
ISSN1672-2124
DOI10.14009/j.issn.1672-2124.2017.05.002

Cover

More Information
Summary:目的:建立超高效液相色谱-串联质谱法和同位素稀释内标法分析人血浆中利奈唑胺浓度的方法.方法:血浆样本经乙腈稀释沉淀蛋白进行前处理,以同位素利奈唑胺-d3为内标,采用Acquity UPLC(c)BEH-C18色谱柱(2.1 mm×50mm,1.7 μm)分离,流动相包括水(含0.1%甲酸,V/V)和乙腈(含0.1%甲酸,V/V),梯度洗脱,流速为0.3 ml/min.正离子检测模式下,采用多离子反应监测模式进行分析.结果:利奈唑胺浓度在0.078~10.000 μg/ml范围内线性关系良好,定量限为0.078 μg/ml;日内、日间RSD均<6%;提取回收率〉90%.结论:本方法操作简便、快速、准确、专属性强且稳定性良好,适用于人血浆中利奈唑胺浓度的分析,可用于临床治疗药物监测.
Bibliography:Objective:To establish a method for analysis of content of linezolid in human plasma by ultra performance liquid chromatography-tandem mass spectrometry with isotopes dilution.METHODS: Plasma samples were disposed by acetonitrile dilution protein deposition,isotope rina thiazole amine-d3 was set as internal control,and Acquity UPLC(c)BEH-C18 column(2.1 mm×50 mm,1.7 μm)was adopted,the mobile phase consisted of water(0.1%formic acid,V/V)and acetonitrile(0.1%formic acid,V/V)in gradient elution,at flow rate of 0.3 ml/min.Under positive ion detection mode,multiple ion reaction monitoring mode was adopted for analysis.RESULTS: The content of linezolid showed good linear relationship within 0.078 μg/ml-10.000 μg/ml,the limit of quantitation was 0.078 μg/ml.And RSD of intra-and inter-day precision 〈6%,the recovery 〉90%.CONCLUSIONS: This method is simple,rapid and accurate with strong specificity and good stability,which can be used for analysis of content of linezolid in human plasma and clinical therapeutic drug mon
ISSN:1672-2124
DOI:10.14009/j.issn.1672-2124.2017.05.002